1. Morphological and physiological aspects of renal function are share
d by humans and swine. SK&F 101926 is a potent antagonist of vasopress
in binding to V2 receptors and vasopressin stimulation of adenylate cy
clase activity in renomedullary membranes from both species. 2. Unexpe
ctedly, SK&F 101926 proved to be an antidiuretic agonist in humans. He
nce, we evaluated SK&F 101926 for antidiuretic agonist and antagonist
activities in conscious domestic pigs. 3. During water diuresis (U(osm
) < 230 mOsm/kg H2O), administration of SK&F 101926 (100 mug/kg, i.v.)
produced a maximal U(osm) of 192 +/- 18 mOsm/kg H2O, a concentration
not significantly different from that in vehicle-treated pigs. 4. In h
ydropenia, SK&F 101926 produced a modest decrease in U(osm), from 945
to 629 mOsm/kg H2O (P < 0.05). 5. In in vitro studies subsequently per
formed using renomedullary tissue from the same pigs, SK&F 101926 disp
layed high affinity for V2 receptors (K(bind) = 11.8 nM) and high pote
ncy to inhibit vasopressin-stimulation of adenylate cyclase (K(i) = 3.
9 nM). 6. No activity of SK&F 101926 to stimulate adenylate cyclase ac
tivity was detected. 7. We conclude that, in spite of its activity in
in vitro assays, SK&F 101926 is a weak antidiuretic antagonist in dome
stic pigs. 8. These results underscore the limited utility of assessme
nts of vasopressin receptor binding and vasopressin-stimulated adenyla
te cyclase activities in vitro to predict functional antidiuretic acti
vities in vivo.